Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $57.00 at Morgan Stanley

Celldex Therapeutics (NASDAQ:CLDX) had its price objective boosted by analysts at Morgan Stanley from $50.00 to $57.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target would indicate a potential upside of 70.10% from the company’s previous close.

A number of other equities analysts also recently weighed in on CLDX. HC Wainwright raised their target price on shares of Celldex Therapeutics from $42.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday. Barclays boosted their price target on Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Guggenheim raised their price objective on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Stifel Nicolaus set a $68.00 price objective on Celldex Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald boosted their target price on Celldex Therapeutics from $61.00 to $72.00 and gave the stock an “overweight” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $59.75.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $33.51 on Wednesday. The firm’s 50-day moving average price is $39.03 and its 200-day moving average price is $34.84. The company has a market capitalization of $2.63 billion, a PE ratio of -7.70 and a beta of 0.84. Celldex Therapeutics has a 1-year low of $22.10 and a 1-year high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.73 million. Equities analysts anticipate that Celldex Therapeutics will post -4.17 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Quantinno Capital Management LP lifted its holdings in shares of Celldex Therapeutics by 178.7% during the first quarter. Quantinno Capital Management LP now owns 65,744 shares of the biopharmaceutical company’s stock valued at $2,085,000 after purchasing an additional 42,158 shares in the last quarter. Bank of America Corp DE raised its position in Celldex Therapeutics by 70.8% in the 1st quarter. Bank of America Corp DE now owns 708,647 shares of the biopharmaceutical company’s stock worth $22,478,000 after buying an additional 293,759 shares during the last quarter. First Trust Advisors LP lifted its stake in Celldex Therapeutics by 78.7% during the 1st quarter. First Trust Advisors LP now owns 68,470 shares of the biopharmaceutical company’s stock valued at $2,172,000 after acquiring an additional 30,157 shares during the period. Sei Investments Co. bought a new position in Celldex Therapeutics during the 1st quarter valued at about $1,210,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Celldex Therapeutics during the 1st quarter valued at about $929,000.

Key Headlines Impacting Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Barzolvolimab achieved the main goals in both Phase 3 trials. Celldex reported that EMBARQ-CSU1 and EMBARQ-CSU2 met their primary and all key secondary endpoints in chronic spontaneous urticaria, including statistically significant improvements in weekly urticaria activity scores at Week 12. Benefits were also reported in patients who had failed omalizumab and those with severe disease or angioedema. Celldex Phase 3 results announcement
• Positive Sentiment: The results support a potential 2027 regulatory filing. Celldex said efficacy was sustained or deepened through Week 24 and that both trials will continue to Week 52. Management expects to submit a biologics license application in 2027, potentially positioning barzolvolimab as a major commercial opportunity in CSU. Reuters report on Celldex trial results
• Positive Sentiment: Analysts raised their valuation targets. HC Wainwright lifted its target from $42 to $64 with a Buy rating, while Cantor Fitzgerald raised its target from $61 to $72 and maintained an Overweight rating. These targets imply substantial upside if the clinical results translate into approval and commercial success.
• Neutral Sentiment: The stock’s reaction was counterintuitive. Reports described a decline following the readout, likely reflecting profit-taking and very high expectations ahead of the catalyst rather than clearly negative efficacy data. Investors may now be shifting attention toward approval timing, launch potential and longer-term safety.
• Negative Sentiment: Safety concerns overshadowed the trial win. Some investors questioned the safety profile of barzolvolimab, even though Celldex characterized the drug as well tolerated through 24 weeks and said the profile was consistent with earlier studies. Unresolved safety concerns could affect regulatory review and the drug’s eventual market adoption. Economic Times report on safety concerns

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for diseases with significant unmet medical needs. The company’s research programs address conditions in immunology, inflammation, oncology and other areas where targeted immune-system modulation may provide therapeutic benefits.

Celldex’s lead investigational product is barzolvolimab, an antibody designed to block the KIT receptor and reduce mast cells. The therapy is being studied in immune-mediated diseases, including chronic spontaneous urticaria and prurigo nodularis.